Since FGFs, in particular FGF2, are under the control of E2 in breast cancer [19], we examined whether E2 could also be a factor in FGF pathway signaling in NSCLC, which is often positive for ER expression [10, 14, 15, 17, 25]. The gene discussed is ESR1; the disease is breast carcinoma.